Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.28−0.02 (-0.22%)
Close on Nov 19, 2026Market cap $533.01MP/E –Yield –
Climb Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Climb Bio's free cash flow for the twelve months ending Dec 31, 2025 was -$54.54M. For fiscal 2025 it was -$54.54M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$54.54M | – |
| FY2024 | Dec 31, 2024 | -$15.56M | – |
| FY2023 | Dec 31, 2023 | -$20.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$15.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.25M | -450.9% |
| Q4 FY2024 | Dec 31, 2024 | -$5.52M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$947.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $3.49M | – |
See a number that looks wrong?